RxDoctor Payments Data

Steven Ellis, MD

Clinical Neurophysiology · Springfield, MONPI 1821431123

Payments from drug & device makers

$10,471in general payments, 2019–2025

Across 538 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$977
  • Medtronic$637
  • Jazz Pharmaceuticals Inc.$534
  • Sanofi$462
  • Argenx US, Inc.$404
  • plus $6K from 52 others

What the payments were for

  • Speaking & faculty fees$190%
  • Travel & lodging$7627%
  • Food & beverage$9,50991%
  • Education$1812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)105$1,850
Livanova USA, Inc.10$977
Medtronic(2 entities)11$637
Jazz Pharmaceuticals Inc.29$534
Sanofi25$462
Argenx US, Inc.21$404
EMD Serono, Inc.23$403
UCB, Inc.19$342
Pfizer20$287
Novartis13$268
Amgen(2 entities)12$244
Acadia Pharmaceuticals Inc18$244
Amneal Pharmaceuticals LLC15$236
Biohaven Pharmaceutical Holding Company Ltd.26$234
Neurocrine Biosciences, Inc.11$220
Supernus Pharmaceuticals, Inc.15$206
ANI Pharmaceuticals, Inc.9$186
Biogen9$176
Kyowa Kirin, Inc.11$176
Lundbeck LLC9$141
Teva Pharmaceuticals USA, Inc.8$137
Avion Pharmaceuticals7$136
AstraZeneca(2 entities)8$135
Biohaven Pharmaceuticals, Inc.14$130
Amylyx Pharmaceuticals, Inc.5$122
Eisai Inc.7$120
Sanofi-aventis U.S. LLC2$113
SK Life Science, Inc.5$100
Lilly USA, LLC6$89
MDD US Operations, LLC6$89
Xeris Pharmaceuticals, Inc.4$87
CSL Behring4$79
Tanabe Pharma America, Inc.5$79
Harmony Biosciences LLC3$75
Acorda Therapeutics, Inc3$63
Mallinckrodt Hospital Products Inc.3$53
Piramal Critical Care1$53
Adamas Pharmaceuticals, Inc.3$52
Grifols USA, LLC3$51
Johnson & Johnson3$49
Banner Life Sciences, LLC2$43
Abbott2$39
Catalyst Pharmaceuticals, Inc.2$38
Otsuka America Pharmaceutical, Inc.2$36
Averitas Pharma Inc.2$35
Vanda Pharmaceuticals Inc.1$34
Ipsen Biopharmaceuticals, Inc2$29
Corium, LLC3$23
Sunovion Pharmaceuticals Inc.2$21
Boston Scientific1$20
Portola Pharmaceuticals, LLC1$19
Upsher-smith Laboratories LLC1$17
TG Therapeutics, Inc.1$16
Aprecia Pharmaceuticals, LLC1$15
Sumitomo Pharma America, Inc.1$15
Amicus Therapeutics, Inc.1$13
Impel Pharmaceuticals Inc.1$12
Ambu Inc.1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$98,946
Medicare patients
621
Services billed
1,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate167$185,692
NuplazidPimavanserin Tartrate30$175,159
Emgality PenGalcanezumab-Gnlm176$169,136
RytaryCarbidopa/Levodopa36$76,726
UbrelvyUbrogepant64$70,466
AustedoDeutetrabenazine12$67,500
QuliptaAtogepant52$66,699
Aimovig AutoinjectorErenumab-Aooe71$64,353
FingolimodFingolimod Hcl15$62,285
NourianzIstradefylline15$45,698
EliquisApixaban44$43,320
BriviactBrivaracetam21$32,195
Rasagiline Mesylate142$32,099
Carbidopa-LevodopaCarbidopa/Levodopa814$23,983
Teriflunomide18$23,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$287$229,013211 claims
Acadia Pharmaceuticals IncNuplazid$244$175,15930 claims
AbbVieUbrelvy, Qulipta, Namzaric$1,850$144,142128 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$236$84,897141 claims
Teva Pharmaceuticals USA, Inc.Austedo$137$67,50012 claims
Kyowa Kirin, Inc.Nourianz$176$45,69815 claims
UCB, Inc.Briviact$342$32,19521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Missourion file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Springfield

Where these figures come from

Is this you, or does something look wrong? →